Episode
Episode 164 - Natalia Misciattelli - CEO of AAVantgarde
- Podcast
- The BioHub - by Avetix
- Published
- Apr 29, 2026
- Duration seconds
- 1076
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-164-natalia-misciattelli-ceo-of-aavantgarde/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-biohub-by-avetix-7252289/episode-164-natalia-misciattelli-ceo-of-aavantgarde.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
On this episode we discuss the AAVantgarde story with CEO, Natalia Misciatelli. Founded by Professor Alberto Auricchio in 2021 as a spin-out from Telethon Institute of Genetics and Medicine in Naples, we discuss their dual-vector and intein-based platforms and how the team are positioning to deliver large therapeutic genes for inherited retinal diseases. Backed by household VC names including; Forbion, Atlas Venture, & Sofinnova, Natalia and the team are pursuing game-changing prospects for Stargardt & Usher1b patients. Check this episode out to hear more about their programs, particularly ahead of ARVO where the team will share data from their LUCE ph1/2 study in Usher1b.